Dr. Peeters on KRAS/NRAS Mutations in mCRC

Marc Peeters, MD, PhD
Published: Thursday, Feb 06, 2014

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses an analysis of RAS mutations in the phase III study 20050181, which compared panitumumab plus FOLFIRI versus FOLFIRI for second-line treatment of metastatic colorectal cancer (mCRC).

Peeters says before patients with mCRC are treated with anti-EGFR agents, they are tested for KRAS exon 2 status of their tumor. If the patient has a mutated tumor, they are not treated with anti-EGFR agents such as panitumumab or cetuximab.

In an analysis of the phase III study 20050181, researchers first looked for the wild-type patients in KRAS exon 2 and then looked at the exon 3 and exon 4 in the KRAS genes and NRAS genes, Peeters says. The analysis showed an additional 18% of new mutations outside the KRAS exon 2 gene. Further analysis showed that if a patient has a mutated tumor, there is no benefit but there is also no harm when a patient is treated with panitumumab plus FOLFIRI. If patients have a wild-type RAS tumor, the analysis showed that there is a clear benefit in progression-free survival and overall survival when panitumumab is combined with FOLFIRI, Peeters says.

Marc Peeters, MD, PhD, department of oncology, Antwerp University Hospital, Antwerpen, Belgium, discusses an analysis of RAS mutations in the phase III study 20050181, which compared panitumumab plus FOLFIRI versus FOLFIRI for second-line treatment of metastatic colorectal cancer (mCRC).

Peeters says before patients with mCRC are treated with anti-EGFR agents, they are tested for KRAS exon 2 status of their tumor. If the patient has a mutated tumor, they are not treated with anti-EGFR agents such as panitumumab or cetuximab.

In an analysis of the phase III study 20050181, researchers first looked for the wild-type patients in KRAS exon 2 and then looked at the exon 3 and exon 4 in the KRAS genes and NRAS genes, Peeters says. The analysis showed an additional 18% of new mutations outside the KRAS exon 2 gene. Further analysis showed that if a patient has a mutated tumor, there is no benefit but there is also no harm when a patient is treated with panitumumab plus FOLFIRI. If patients have a wild-type RAS tumor, the analysis showed that there is a clear benefit in progression-free survival and overall survival when panitumumab is combined with FOLFIRI, Peeters says.


View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 1st Annual European Congress on Hematology™: Focus on Lymphoid MalignanciesJan 30, 20182.0
Medical Crossfire®: The Expanding Role of PARP Inhibitors in the Treatment of Ovarian Cancers – Current Strategies and Future DirectionJan 30, 20181.5
Publication Bottom Border
Border Publication
x